Onasemnogene abeparvovec
Also known as: Zolgensma · Itvisma
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, the product Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older. Also in the European Union, the product Zolgensma is indicated for the treatment of patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and either a clinical diagnosis of SMA Type 1 or up to 3 copies of the SMN2 gene. Onasemnogene abeparvovec is listed by the cited source as having an approved use for unspecified spinal muscular atrophy.
Source: European Medicines Agency (EMA), Itvisma — EPAR, 02/10/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Zolgensma — EPAR, 21/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 2170226 onasemnogene abeparvovec
- EMA
- EMEA/H/C/004750, EMEA/H/C/006498
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Itvisma
Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older.
Source: European Medicines Agency (EMA), Itvisma — EPAR, 02/10/2026. © European Medicines Agency.
Document date: 02/10/2026 · Official document →
EMA (EU) Zolgensma
Zolgensma is indicated for the treatment of: patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
Source: European Medicines Agency (EMA), Zolgensma — EPAR, 21/08/2026. © European Medicines Agency.
Document date: 21/08/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Spinal muscular atrophy Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Onasemnogene abeparvovec approved for in the European Union?
Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older. (Source: European Medicines Agency (EMA), Itvisma — EPAR, 02/10/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Itvisma — EPAR, 02/10/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Zolgensma — EPAR, 21/08/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.